Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Plasma Transfusion From Exercise-trained Donors in Patients With Early Alzheimer's Disease (ExPlas)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05068830
Recruitment Status : Recruiting
First Posted : October 6, 2021
Last Update Posted : October 6, 2021
Sponsor:
Collaborator:
St. Olavs Hospital
Information provided by (Responsible Party):
Norwegian University of Science and Technology

Brief Summary:

Introduction Given that exercise training reduces the risk of developing Alzheimer's disease (AD), induces changes in the blood composition and has widespread systemic benefits, it is reasonable to hypothesize that exercised plasma may have rejuvenative properties. The main objective is to test safety and tolerability of transfusing exercised plasma (ExPlas) from young, healthy, fit adults to patients with early AD. The study is a pilot for a future efficacy study. The key secondary objectives are examining the effect of plasma transfusions on cognitive function, fitness level, vascular risk profile, assessment of cerebral blood flow and hippocampal volume, quality of life, functional connectivity assessed by resting state functional MRI and biomarkers in blood and cerebrospinal fluid.

Methods and analysis ExPlas is a double-blinded, randomized controlled clinical single center trial. Patients aged 50-75 years with diagnosis mild cognitive impairment or early AD will be recruited from two Norwegian hospitals. ExPlas is plasma drawn by plasmapheresis once a month for 4 months, from a total of 30 donors (aged 18-40, BMI ≤27 kg/m2 and VO2max >50 mL/kg/min). All units will be virus inactivated by the Intercept method in accordance with procedures at St. Olavs Hospital. Comparison with isotonic saline allows differentiation from a non-blood product. The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions divided over three 4-weeks periods during study year-1. Follow-up examinations after 2 and 5 years after baseline is also planned.

Ethics and dissemination Written informed consent will be obtained from all participants and participation is voluntary. All participants have a next of kin who will follow them throughout the study and represent the patient's interest. The study is approved by the Regional Committee for Medical and Health Research Ethics (REK 2018/702) and the Norwegian Medicines Agency (EudraCT No. 2018-000148-24).


Condition or disease Intervention/treatment Phase
Alzheimer Disease Drug: ExPlas Drug: Octaplasma Drug: Saline Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Double blinded, randomized controlled clinical phase II trial
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Plasma Transfusion From Exercise-trained Donors in Patients With Early Alzheimer's Disease: The ExPlas Study
Actual Study Start Date : September 17, 2021
Estimated Primary Completion Date : September 2024
Estimated Study Completion Date : September 2025


Arm Intervention/treatment
Experimental: Exercised plasma (ExPlas)
Dosage: 200 mL at every time point Dosage form: Solution for intravenous infusion Frequency of administration: 12 ExPlas transfusions during the time span of one year (weekly transfusions in 3 four-week periods)
Drug: ExPlas

ExPlas (plasma from fit donors) is a Investigational Medicinal Product. ExPlas is plasma drawn by plasmapheresis once a month for 4 months, from a total of 30 donors (aged 18-40, BMI ≤27 kg/m2 and VO2max >50 mL/kg/min) at the Blood Bank at St. Olavs Hospital. All unites will be virus inactivated by the Intercept method (Cerus corporation, US) in accordance with the procedures at Blood Bank at St. Olavs Hospital.

The transfusion volume will be 200 mL at every time point.

The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline.


Active Comparator: Octaplasma
Dosage: 200 mL at every time point Dosage form: Solution for intravenous infusion Frequency of administration: 12 Octaplasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods)
Drug: Octaplasma

Octaplasma is defined as a Investigational Medicinal Product. Octaplasma is human pooled plasma produced by Octapharma (Lachen, Switzerland). The transfusion volume will be 200 mL at every time point .

The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline.


Placebo Comparator: Saline
Dosage: 200 mL at every time point Dosage form: Solution for intravenous infusion Frequency of administration: 12 saline infusions during the time span of one year (weekly transfusions in 3 four-week periods)
Drug: Saline

Saline is provided by the hospital pharmacies in Central Norway. The infusion volume will be 200 mL at every time point.

The main study consists of 6 rounds of examinations in addition to 12 saline infusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline.





Primary Outcome Measures :
  1. Number of patients with adverse events [ Time Frame: 1 year ]
    as a measure for safety and tolerability of the treatment

  2. Number of subjects who comply with the research protocol [ Time Frame: 1 year ]
    as a measure for feasibility


Secondary Outcome Measures :
  1. CERAD-test [ Time Frame: 1, 2 and 5 years ]
    Change in performance in the CERAD (The Consortium to Establish a Registry for Alzheimer's Disease) Ten word Test. CERAD Word List consists of three test parts; immediate recall, delayed recall and recognition. The scoring range for immediate recall is 0-30, for delayed recall 0-10 and for recognition 0-20. Higher scores indicate better learning performance, memory performance and recognition performance.

  2. MMSE [ Time Frame: 1, 2, and 5 years ]
    Change in the Mini-Mental State Examination Score. An MMSE score of ≥20 is criteria for inclusion. Higher scores >28 indicate normal cognitive function. Scores in the middle range 25-27 may indicate cognitive impairment. Lower scores <24 indicate cognitive impairment.

  3. Trail-Making test A and B [ Time Frame: 1, 2, and 5 years ]
    Change in performance in Trail-Making test A and B. The Trail Making Tests are scored by how long it takes to complete the tests. Norms for completion time variate with age and educational level. Longer completion time indicates impaired visual attention, processing speed and executive function.

  4. Clock Drawing Test [ Time Frame: 1, 2, and 5 years ]
    Change in scores in the Clock Drawing Test. The Clock Drawing Test has a scoring range 0-5. Higher scores indicate normal cognitive function. Lower scores <4 may indicate cognitive impairment, spatial dysfunction or neglect.

  5. Controlled Oral Word Association Test (COWAT)-FAS [ Time Frame: 1, 2, and 5 years ]
    Change in scores in Controlled Oral Word Association Test (COWAT)-FAS. Scoring is based on how many words the person produces within 1 minute. The minimum score is 0, and there is no maximum score. Higher scores indicate better verbal fluency. Scoring norms are based on the persons age and education level.

  6. Visual Object and Space Perception (VOSP) Silhouettes [ Time Frame: 1, 2, and 5 years ]
    Change in scores in Visual Object and Space Perception (VOSP) Silhouettes. Visual Object and Space Perception (VOSP) Silhouettes has a scoring range 0-30. Higher scores > 20 indicate normal visuospatial function, and lower scores < 20 indicate visuospatial dysfunction.

  7. Clinical Dementia Rating Scale Global score and Sum of Boxes [ Time Frame: 1, 2, and 5 years ]
    Change in Clinical Dementia Rating Scale Global score and Sum of Boxes. Clinical Dementia Rating Scale (CDR) is a clinical scale for the staging of dementia. The Global Score ranges dementia severity from 0-3. The Sum of Boxes ranges dementia severity from 0-18. Higher scores indicate more severe disease.

  8. The Lawton Instrumental Activities of Daily Living Scale (IADL) [ Time Frame: 1, 2, and 5 years ]
    Change in The Lawton Instrumental Activities of Daily Living Scale (IADL). The Lawton Instrumental Activities of Daily Living Scale (IADL) evaluates the person's ability to perform complex everyday activities. The score ranges from 8-31. Higher scores indicate lower functional level.

  9. 6 minutes' walk test [ Time Frame: 1, 2, and 5 years ]
    Change in 6 minutes' walk-test

  10. Functional MRI [ Time Frame: 1, 2, and 5 years ]
    Change in/Reduced hippocampal atrophy and preservation of functional connectivity assessed by resting state functional MRI. A secondary aim is to identify any effect of treatment group on MRI markers of both neurodegenerative and cerebrovascular disease.

  11. SF-36 [ Time Frame: 1, 2, and 5 years ]
    Quality of Life SF-36 Questionnaire. Computer-based scoring services for the SF-36v2 are available through QualityMetric™ or its licensed certified vendors.

  12. Biomarker profile in blood [ Time Frame: 1, 2, and 5 years ]
    Change in biomarkers in blood (APOE). As there exist no single ideal biomarker of AD this endpoint is partly exploratory. Biological material will be stored for future analysis in the search for new biomarkers.

  13. Biomarker profile in cerebrospinal fluid [ Time Frame: 1, 2, and 5 years ]
    Change in biomarkers in cerebrospinal fluid (Amyloid Beta 1-42, Amyloid Beta 1-40, phosphor tau and total tau). As there exist no single ideal biomarker of AD this endpoint is partly exploratory. Biological material will be stored for future analysis in the search for new biomarkers.

  14. Echocardiography - Cardiac dimensions - Left ventricular end diastolic diameter [ Time Frame: 1, 2, and 5 years ]
    Changes in cardiac dimensions - left ventricular end diastolic diameter (mm).

  15. Echocardiography - Cardiac dimensions - Right ventricular dimension [ Time Frame: 1, 2, and 5 years ]
    Changes in cardiac dimensions - right ventricular dimension (mm).

  16. Echocardiography - Cardiac volumes - Left ventricular and diastolic volume. [ Time Frame: 1, 2, and 5 years ]
    Changes in cardiac volumes - left ventricular and diastolic volume (mL).

  17. Echocardiography - Cardiac volumes - Right ventricular volume [ Time Frame: 1, 2, and 5 years ]
    Changes in cardiac volumes. Right ventricular volume (mL).

  18. Echocardiography - Functional indices - Ejection fraction [ Time Frame: 1, 2, and 5 years ]
    Changes in functional indices - ejection fraction (%).

  19. Echocardiography - Functional indices - Left ventricular strain [ Time Frame: 1, 2, and 5 years ]
    Changes in functional indices - left ventricular strain (%).

  20. Echocardiography - Functional indices - Ventricular velocity [ Time Frame: 1, 2, and 5 years ]
    Changes in functional indices - ventricular velocity (cm/s).

  21. Echocardiography - Functional indices - Right ventricular strain [ Time Frame: 1, 2, and 5 years ]
    Changes in functional indices - right ventricular strain (%).

  22. Echocardiography - Functional indices - Left ventricular stiffness [ Time Frame: 1, 2, and 5 years ]
    Changes in functional indices - left ventricular stiffness.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Patient inclusion criteria:

  • Diagnosis AD in early phase according to the IWG-2 criteria.
  • Mini-Mental State Examination (MMSE) Score ≥20.
  • In-vivo evidence of Alzheimer´s pathology (one of the following):

    • Decreased Aβ42 together with increased t-tau or p-tau in CSF.
    • Increased tracer retention on amyloid PET.
  • Availability of a next of kin who knows the patient well and is willing to accompany the subject to all trial visits and give information about the patients functional level.
  • Signed informed consent.
  • The patient is judged fitted for the study and capable to cooperate in treatment and follow-up.
  • Ability to communicate in Norwegian or another Scandinavian language.

Patient exclusion criteria:

  • Pregnancy or unwilling to use adequate birth control for the duration of and 6 months beyond study participation. Defined according to Clinical Trial Facilitation Group document "Recommendations related to contraception and pregnancy testing in clinical trials".
  • Positive for Hepatitis B, Hepatitis C or HIV at screening.
  • Not qualified to give consent at inclusion.
  • Any other condition judged to interfere with the safety of the patient or the intent and conduct of the study.

Related to medical history:

  • Stroke
  • Anaphylaxis
  • Prior adverse reaction to any human blood product
  • Any history of a blood coagulation disorder or hypercoagulability
  • Congestive heart failure, defined as any previous heart failure hospitalization, or current symptomatic heart failure in New York heart Association class ≥II with reduced, mid-range or preserved ejection fraction.
  • Coagulation defect or hypercoagulopathy
  • Uncontrolled hypertension
  • Renal failure
  • Prior intolerance to intravenous fluids
  • Recent history of uncontrolled atrial fibrillation
  • Bone marrow transplant
  • IgA deficiency
  • Severe protein S deficiency
  • Thrombocytopenia (platelets < 40 x 10 to the power of 9/L)
  • Contraindication for Octaplasma

Related to medications or other treatments:

  • Any concurrent use of anticoagulant therapy, clopidogrel or acetylsalicylic acid/Dipyridamol in combination.
  • Initiation or change in the dosage of a acetylcholine esterase inhibitor (AChEI) or memantine during the trial (week 0-52). Participants will be urged to start on AChEI when diagnosis is communicated, and must be on a stable dose for at least one month prior to screening.
  • Concurrent participation in another treatment trial for AD. If there was prior participation, the last dose of the investigational agent must have been given at least 6 months prior to screening, except if the patient received placebo medication.
  • Treatment with any human blood product, including intravenous immunoglobulin, during the 6 months prior to screening or during the trial.
  • Concurrent daily treatment with benzodiazepines, typical or atypical antipsychotics, long-acting opioids, or other medications that is judged to interfere with cognition. Intermittent treatment with short-acting benzodiazepines or atypical antipsychotics may be permitted, provided that no dose is administered within 72 hours prior to cognitive assessment.

Related to magnetic resonance imaging:

  • Claustrophobia
  • Any metallic surgical implant, like a pacemaker or clip that is incompatible with MRI.

Certain metallic implants like joint replacements may be permitted, provided that specific manufacturer specifications are available, and that the device is known to be safe for 7T MRI. In case a patient is not eligible for the 7T scanner, the 3T scanner will be used.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05068830


Contacts
Layout table for location contacts
Contact: Atefe R. Tari +47 48079041 atefe.r.tari@ntnu.no

Locations
Layout table for location information
Norway
Department of Neurology and Clinical Neurophysiology, St Olavs Hospital Recruiting
Trondheim, Norway
Contact: Sigrid Botne Sando, MD, PhD       sigrid.b.sando@ntnu.no   
Sponsors and Collaborators
Norwegian University of Science and Technology
St. Olavs Hospital
Investigators
Layout table for investigator information
Principal Investigator: Ulrik Wisløff, PhD, Prof Cardiac Exercise Research Group at the Department of Circulation and Medical Imaging, NTNU
Principal Investigator: Sigrid Botne Sando, MD, PhD Department of Neurology and Clinical Neurophysiology, St. Olavs University Hospital
Layout table for additonal information
Responsible Party: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT05068830    
Other Study ID Numbers: 2018/702
2018-000148-24 ( EudraCT Number )
First Posted: October 6, 2021    Key Record Dates
Last Update Posted: October 6, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: To be decided
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: After study completion
Access Criteria: Collaborative research projects

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Norwegian University of Science and Technology:
Exercise therapy
Blood transfusion
Plasma
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders